198 related articles for article (PubMed ID: 19506994)
1. Triple negative breast cancer: clinicopathological characteristics and treatment strategies.
Akiyama F; Iwase H
Breast Cancer; 2009; 16(4):252-3. PubMed ID: 19506994
[TBL] [Abstract][Full Text] [Related]
2. Clinicopathological characteristics of triple-negative breast cancers.
Sasaki Y; Tsuda H
Breast Cancer; 2009; 16(4):254-9. PubMed ID: 19657711
[TBL] [Abstract][Full Text] [Related]
3. "Targeting" triple-negative breast cancer: the lessons learned from BRCA1-associated breast cancers.
Nanda R
Semin Oncol; 2011 Apr; 38(2):254-62. PubMed ID: 21421115
[TBL] [Abstract][Full Text] [Related]
4. Clinical significance of basal-like subtype in triple-negative breast cancer.
Yamamoto Y; Ibusuki M; Nakano M; Kawasoe T; Hiki R; Iwase H
Breast Cancer; 2009; 16(4):260-7. PubMed ID: 19701681
[TBL] [Abstract][Full Text] [Related]
5. Triple negative, basal cell type and EGFR positive invasive breast carcinoma in Kuwaiti and British patients.
Ayad E; Francis I; Peston D; Shousha S
Breast J; 2009; 15(1):109-11. PubMed ID: 19077133
[No Abstract] [Full Text] [Related]
6. Potential chemotherapy options in the triple negative subtype of breast cancer.
Altundag K; Harputluoglu H; Aksoy S; Gullu IH
J Clin Oncol; 2007 Apr; 25(10):1294-5; author reply 1295-6. PubMed ID: 17401026
[No Abstract] [Full Text] [Related]
7. Triple-negative breast cancer: risk factors to potential targets.
Schneider BP; Winer EP; Foulkes WD; Garber J; Perou CM; Richardson A; Sledge GW; Carey LA
Clin Cancer Res; 2008 Dec; 14(24):8010-8. PubMed ID: 19088017
[TBL] [Abstract][Full Text] [Related]
8. Triple negative and basal-like breast cancer in East Africa.
Trinkaus ME; Sayed S; Gakinya SM; Moloo Z; Hanna W; Rahim Y
Breast J; 2011; 17(4):438-40. PubMed ID: 21752138
[No Abstract] [Full Text] [Related]
9. The association of infrared imaging findings of the breast with hormone receptor and human epidermal growth factor receptor 2 status of breast cancer.
Wang J; Shih TT; Yen RF; Lu YS; Chen CY; Mao TL; Lin CH; Kuo WH; Tsai YS; Chang KJ; Chien KL
Acad Radiol; 2011 Feb; 18(2):212-9. PubMed ID: 21126889
[TBL] [Abstract][Full Text] [Related]
10. What is the difference between triple-negative and basal breast cancers?
Seal MD; Chia SK
Cancer J; 2010; 16(1):12-6. PubMed ID: 20164685
[TBL] [Abstract][Full Text] [Related]
11. ERCC1 expression in triple negative breast carcinoma: the paradox revisited.
Sidoni A; Cartaginese F; Colozza M; Gori S; Crinó L
Breast Cancer Res Treat; 2008 Oct; 111(3):569-70. PubMed ID: 17987380
[No Abstract] [Full Text] [Related]
12. Possible treatment strategies for triple-negative breast cancer on the basis of molecular characteristics.
Kurebayashi J
Breast Cancer; 2009; 16(4):275-80. PubMed ID: 19408071
[TBL] [Abstract][Full Text] [Related]
13. Therapeutic strategies for triple-negative breast cancer.
Tan AR; Swain SM
Cancer J; 2008; 14(6):343-51. PubMed ID: 19060597
[TBL] [Abstract][Full Text] [Related]
14. Response to neoadjuvant therapy and disease free survival in patients with triple-negative breast cancer.
Wang S; Yang H; Tong F; Zhang J; Yang D; Liu H; Cao Y; Liu P; Zhou P; Cheng L; Liu M; Guo J
Gan To Kagaku Ryoho; 2009 Feb; 36(2):255-8. PubMed ID: 19223741
[TBL] [Abstract][Full Text] [Related]
15. Impact of decalcification on receptor status in breast cancer.
Darvishian F; Singh B; Krauter S; Chiriboga L; Gangi MD; Melamed J
Breast J; 2011; 17(6):689-91. PubMed ID: 21999708
[No Abstract] [Full Text] [Related]
16. Commentary: hormone receptor testing in breast cancer: a distress signal from Canada.
Allred DC
Oncologist; 2008 Nov; 13(11):1134-6. PubMed ID: 18987048
[No Abstract] [Full Text] [Related]
17. Vitamin D intake may be effective in the management of triple-negative breast cancer.
Harputluoglu H; Dizdar O; Karaahmet F; Altundag K
J BUON; 2011; 16(3):569. PubMed ID: 22006770
[No Abstract] [Full Text] [Related]
18. In early-stage breast cancer, the estrogen receptor interacts with correlation between human epidermal growth factor receptor 2 status and age at diagnosis, tumor grade, and lymph node involvement.
Neven P; Brouckaert O; Van Belle V; Vanden Bempt I; Hendrickx W; Cho H; Deraedt K; Van Calster B; Van Huffel S; Moerman P; Amant F; Leunen K; Smeets A; Wildiers H; Paridaens R; Vergote I; Christiaens MR
J Clin Oncol; 2008 Apr; 26(10):1768-9; author reply 1769-71. PubMed ID: 18519273
[No Abstract] [Full Text] [Related]
19. Triple negative endometrial cancer may be more sensitive to platinum based chemotherapy.
Altundag O; Dursun P; Roach EC; Altundag K
J BUON; 2013; 18(1):289. PubMed ID: 23613418
[No Abstract] [Full Text] [Related]
20. Eukaryotic initiation factor 4E overexpression in triple-negative breast cancer predicts a worse outcome.
Flowers A; Chu QD; Panu L; Meschonat C; Caldito G; Lowery-Nordberg M; Li BD
Surgery; 2009 Aug; 146(2):220-6. PubMed ID: 19628077
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
